Drug
Oxonic Acid clinical trials
- studies test it
- 185
- open now
- 29
- in phase 3
- 29
- first study started
- 2002
Keep track of what changes. Save the Oxonic Acid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
185 studies that test it; most in 2013 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 11 |
| 2007 | 11 |
| 2008 | 10 |
| 2009 | 10 |
| 2010 | 10 |
| 2011 | 8 |
| 2012 | 9 |
| 2013 | 13 |
| 2014 | 7 |
| 2015 | 11 |
| 2016 | 10 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 9 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 10 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 26
- Phase 2
- 142
- Phase 3
- 29
- Phase 4
- 4
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 160
Taiho Oncology, Inc. (9) · Chinese Academy of Medical Sciences (9) · Taiho Pharmaceutical Co., Ltd. (9) · National Cancer Center, Korea (9) · Fudan University (8) · Kansai Hepatobiliary Oncology Group (6) · Yonsei University (5) · Zhejiang Cancer Hospital (5)
Often tested with
Tested in the same studies.
Tegafur (185) · Gimeracil (185) · Oxaliplatin (59) · Paclitaxel (23) · Cisplatin (21) · Gemcitabine (20) · Albumin-Bound Paclitaxel (16) · Leucovorin (14)
Studies
Open first, then newest update. How each study uses Oxonic Acid is read from its arms, and is right about nine times in ten.
Testing it · 185
- Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerRecruitingPhase 2Jinbo YueNCT07007182Written as Capecitabine / S-1 (radiosensitizer during IMRT)
- DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric CancerNot yet recruitingPhase 2Taipei Veterans General Hospital, TaiwanNCT07757191Written as Durvalumab, TS-1
- Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT06519591Written as Cadonilimab, LM-302, S-1, paclitaxel
- IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07483567Written as IBI343,sintilimab,oxaliplatin,S-1
- Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction CancerRecruitingPhase 3Shanghai Shengdi Pharmaceutical Co., LtdNCT07522151Written as Adebrelimab plus S-1 and oxaliplatin
- Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaRecruitingPhase 2Ruijin HospitalNCT07569068Written as Tislelizumab, LM-302 and S-1
- LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory StudyRecruitingPhase 2Ruijin HospitalNCT07556640Written as LM-302, S-1, paclitaxel
- A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric CancerRecruitingPhase 2Asan Medical CenterNCT05184803Written as Docetaxel injection, oxaliplatin, S-1
- Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07507916Written as SOX Chemotherapy
- Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07474324Written as SOX Chemotherapy
- Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingPhase 3Ruijin HospitalNCT07366528Written as Oxaliplatin plus S-1
- A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingPhase 2Hebei Medical UniversityNCT07304258Written as Paclitaxel Injection, S-1, tislelizumab
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingPhase 2Ming-Yuan ChenNCT07070479Written as S-1
- Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/MetastasisNot yet recruitingPhase 4The First Affiliated Hospital with Nanjing Medical UniversityNCT06779318Written as S-1
- Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT06901622Written as Camrelizumab, anlotinib, nab-paclitaxel, S-1
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingPhase 2China Medical University, ChinaNCT06881017Written as S-1
- Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06789679Written as Gemcitabine, albumin-bound paclitaxel, S-1
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingPhase 1/2Chinese PLA General HospitalNCT05218889Written as surufatinib + camrelizumab + nab-paclitaxel + S-1
- A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.Not yet recruitingPhase 2Fujian Cancer HospitalNCT06746545Written as Fruquintinib+S-1
- Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRTNot yet recruitingPhase 2China Medical University HospitalNCT06598917Written as S-1
See all 185 studies that test Oxonic Acid →
Given in every arm · 137 — Oxonic Acid is usual care beside what is tested
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as S-1
- Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard TherapyRecruitingNot applicableNingbo Medical Center Lihuili HospitalNCT07892573Written as S-1
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingPhase 2Shanghai Changzheng HospitalNCT07621484Written as S-1
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Written as S-1
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as S-1
- IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRecruitingPhase 1/2Ruijin HospitalNCT07025889Written as S-1
- Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic CancerNot yet recruitingPhase 2Ruijin HospitalNCT07745790Written as S-1
- Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 2Shanghai General Hospital, ChinaNCT07733050Written as S-1
- Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 1/2Ting LiuNCT07727993Written as S-1
- SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal MetastasisRecruitingPhase 2Ruijin HospitalNCT07384234Written as S-1
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07464756Written as S-1 & Oxaliplatin
- Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyNot yet recruitingPhase 2Zhifeng Zhao, PhDNCT07685704Written as S-1
- Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07038629Written as S1
- Adebrelimab Plus S-1 for Resected CholangiocarcinomaNot yet recruitingPhase 2Xingjun GuoNCT07561775Written as S-1
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingPhase 2Beijing Friendship HospitalNCT07353684Written as SOX Chemotherapy
- Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07515625Written as S-1
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Fudan UniversityNCT07492615Written as S-1 & Oxaliplatin
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingPhase 3AkesoNCT07023315Written as SOX chemotherapy
- Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingPhase 2Sichuan UniversityNCT07374250Written as S-1
- Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Beijing Friendship HospitalNCT07315854Written as SOX Chemotherapy
Showing 20 of 137.
As the comparator · 14 — what is tested is compared with Oxonic Acid
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric CancerRecruitingPhase 2Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT06510010Written as Oxaliplatin With S-1 （SOX）
- Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative PathologyNot yet recruitingPhase 4Liaoning Cancer Hospital & InstituteNCT07161453Written as SOX Chemotherapy
- Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical SurgeryNot yet recruitingPhase 4Liaoning Cancer Hospital & InstituteNCT07149181Written as SOX Chemotherapy
- Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric CancerNot yet recruitingPhase 4Liaoning Cancer Hospital & InstituteNCT07132528Written as SOX Chemotherapy
- Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06454435Written as Sintilimab + S-1 plus nab-paclitaxel
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerRecruitingPhase 3Beijing Konruns Pharmaceutical Co., Ltd.NCT06194734Written as S-1
- S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction AdenocarcinomaRecruitingPhase 2Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT04989985Written as Oxaliplatin+S-1
- PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingPhase 2Fudan UniversityNCT05468138Written as SOX
- Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric CancerCompletedPhase 2Ruijin HospitalNCT03636893Written as SOX Chemotherapy
- Using ctDNA to Guide Treatment Decisions for Stage III Gastric CancerActive, not recruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT06939439Written as SOX Chemotherapy
- Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric CancerStatus unknownPhase 2Chinese PLA General HospitalNCT04367025Written as S1
- A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric CancerStatus unknownPhase 2/3LanZhou UniversityNCT02817425Written as SOX
- Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownPhase 3Chinese Academy of Medical SciencesNCT02319187Written as S1
- Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric CancerStatus unknownPhase 2Hebei Tumor HospitalNCT01718626Written as S1+Docetaxel
Codes
What other systems call Oxonic Acid · ClinicalTrials.gg INT019029
- MeSH (NLM) D010094Oxonic AcidOne source NLM
- UNII (FDA) 5VT6420TIGOTERACILConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010094 | Oxonic Acid | One source NLM |
| UNII (FDA) | 5VT6420TIG | OTERACIL | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.